This XML file does not appear to have any style information associated with it. The document tree is shown below.
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0239474</article-id>
<article-id pub-id-type="publisher-id">PONE-D-20-20126</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject>
<subj-group>
<subject>Diagnostic medicine</subject>
<subj-group>
<subject>Virus testing</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject>
<subj-group>
<subject>Medical conditions</subject>
<subj-group>
<subject>Infectious diseases</subject>
<subj-group>
<subject>Viral diseases</subject>
<subj-group>
<subject>COVID 19</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Physical sciences</subject>
<subj-group>
<subject>Mathematics</subject>
<subj-group>
<subject>Applied mathematics</subject>
<subj-group>
<subject>Algorithms</subject>
<subj-group>
<subject>Machine learning algorithms</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and analysis methods</subject>
<subj-group>
<subject>Simulation and modeling</subject>
<subj-group>
<subject>Algorithms</subject>
<subj-group>
<subject>Machine learning algorithms</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Computer and information sciences</subject>
<subj-group>
<subject>Artificial intelligence</subject>
<subj-group>
<subject>Machine learning</subject>
<subj-group>
<subject>Machine learning algorithms</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Organisms</subject>
<subj-group>
<subject>Viruses</subject>
<subj-group>
<subject>RNA viruses</subject>
<subj-group>
<subject>Coronaviruses</subject>
<subj-group>
<subject>SARS coronavirus</subject>
<subj-group>
<subject>SARS CoV 2</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Microbiology</subject>
<subj-group>
<subject>Medical microbiology</subject>
<subj-group>
<subject>Microbial pathogens</subject>
<subj-group>
<subject>Viral pathogens</subject>
<subj-group>
<subject>Coronaviruses</subject>
<subj-group>
<subject>SARS coronavirus</subject>
<subj-group>
<subject>SARS CoV 2</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject>
<subj-group>
<subject>Pathology and laboratory medicine</subject>
<subj-group>
<subject>Pathogens</subject>
<subj-group>
<subject>Microbial pathogens</subject>
<subj-group>
<subject>Viral pathogens</subject>
<subj-group>
<subject>Coronaviruses</subject>
<subj-group>
<subject>SARS coronavirus</subject>
<subj-group>
<subject>SARS CoV 2</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Organisms</subject>
<subj-group>
<subject>Viruses</subject>
<subj-group>
<subject>Viral pathogens</subject>
<subj-group>
<subject>Coronaviruses</subject>
<subj-group>
<subject>SARS coronavirus</subject>
<subj-group>
<subject>SARS CoV 2</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Computer and information sciences</subject>
<subj-group>
<subject>Artificial intelligence</subject>
<subj-group>
<subject>Machine learning</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Proteins</subject>
<subj-group>
<subject>C-reactive proteins</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Molecular biology</subject>
<subj-group>
<subject>Molecular biology techniques</subject>
<subj-group>
<subject>Artificial gene amplification and extension</subject>
<subj-group>
<subject>Polymerase chain reaction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and analysis methods</subject>
<subj-group>
<subject>Molecular biology techniques</subject>
<subj-group>
<subject>Artificial gene amplification and extension</subject>
<subj-group>
<subject>Polymerase chain reaction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Body fluids</subject>
<subj-group>
<subject>Blood</subject>
<subj-group>
<subject>Blood counts</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Body fluids</subject>
<subj-group>
<subject>Blood</subject>
<subj-group>
<subject>Blood counts</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Physiology</subject>
<subj-group>
<subject>Body fluids</subject>
<subj-group>
<subject>Blood</subject>
<subj-group>
<subject>Blood counts</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A machine learning algorithm to increase COVID-19 inpatient diagnostic capacity</article-title>
<alt-title alt-title-type="running-head">Machine learning algorithm to diagnose COVID-19</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9382-3564</contrib-id>
<name name-style="western">
<surname>Goodman-Meza</surname>
<given-names>David</given-names>
</name>
<role content-type="https://casrai.org/credit/">Conceptualization</role>
<role content-type="https://casrai.org/credit/">Methodology</role>
<role content-type="https://casrai.org/credit/">Writing – original draft</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Rudas</surname>
<given-names>Akos</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6843-1355</contrib-id>
<name name-style="western">
<surname>Chiang</surname>
<given-names>Jeffrey N.</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2776-6458</contrib-id>
<name name-style="western">
<surname>Adamson</surname>
<given-names>Paul C.</given-names>
</name>
<role content-type="https://casrai.org/credit/">Conceptualization</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ebinger</surname>
<given-names>Joseph</given-names>
</name>
<role content-type="https://casrai.org/credit/">Data curation</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Nancy</given-names>
</name>
<role content-type="https://casrai.org/credit/">Data curation</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Botting</surname>
<given-names>Patrick</given-names>
</name>
<role content-type="https://casrai.org/credit/">Data curation</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9895-8636</contrib-id>
<name name-style="western">
<surname>Fulcher</surname>
<given-names>Jennifer A.</given-names>
</name>
<role content-type="https://casrai.org/credit/">Conceptualization</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4568-3613</contrib-id>
<name name-style="western">
<surname>Saab</surname>
<given-names>Faysal G.</given-names>
</name>
<role content-type="https://casrai.org/credit/">Conceptualization</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Brook</surname>
<given-names>Rachel</given-names>
</name>
<role content-type="https://casrai.org/credit/">Conceptualization</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Eskin</surname>
<given-names>Eleazar</given-names>
</name>
<role content-type="https://casrai.org/credit/">Supervision</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>An</surname>
<given-names>Ulzee</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kordi</surname>
<given-names>Misagh</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<role content-type="https://casrai.org/credit/">Software</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Jew</surname>
<given-names>Brandon</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Balliu</surname>
<given-names>Brunilda</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chen</surname>
<given-names>Zeyuan</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6881-5770</contrib-id>
<name name-style="western">
<surname>Hill</surname>
<given-names>Brian L.</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rahmani</surname>
<given-names>Elior</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Halperin</surname>
<given-names>Eran</given-names>
</name>
<role content-type="https://casrai.org/credit/">Formal analysis</role>
<role content-type="https://casrai.org/credit/">Methodology</role>
<role content-type="https://casrai.org/credit/">Supervision</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref>
<xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref>
<xref ref-type="fn" rid="econtrib001">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Manuel</surname>
<given-names>Vladimir</given-names>
</name>
<role content-type="https://casrai.org/credit/">Conceptualization</role>
<role content-type="https://casrai.org/credit/">Methodology</role>
<role content-type="https://casrai.org/credit/">Supervision</role>
<role content-type="https://casrai.org/credit/">Writing – review & editing</role>
<xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref>
<xref ref-type="aff" rid="aff010">
<sup>10</sup>
</xref>
<xref ref-type="fn" rid="econtrib001">
<sup>‡</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff001">
<label>1</label>
<addr-line>Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff002">
<label>2</label>
<addr-line>Department of Computational Medicine, UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff003">
<label>3</label>
<addr-line>Faculty of Informatics, Eötvös Loránd University (ELTE), Budapest, Hungary</addr-line>
</aff>
<aff id="aff004">
<label>4</label>
<addr-line>Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff005">
<label>5</label>
<addr-line>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff006">
<label>6</label>
<addr-line>Department of Computer Science, UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff007">
<label>7</label>
<addr-line>Department of Human Genetics, UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff008">
<label>8</label>
<addr-line>Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff009">
<label>9</label>
<addr-line>Faculty Practice Group, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America</addr-line>
</aff>
<aff id="aff010">
<label>10</label>
<addr-line>UCLA Clinical and Translational Science Institute, Los Angeles, California, United States of America</addr-line>
</aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Urbanowicz</surname>
<given-names>Ryan J.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>University of Pennsylvania, UNITED STATES</addr-line>
</aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>No authors have competing interests.</p>
</fn>
<fn fn-type="other" id="econtrib001">
<p>‡ These authors jointly supervised the work.</p>
</fn>
<corresp id="cor001">
* E-mail:
<email xlink:type="simple">dgoodman@mednet.ucla.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>15</volume>
<issue>9</issue>
<elocation-id>e0239474</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>6</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>9</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Goodman-Meza et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>
This is an open access article distributed under the terms of the
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0239474"/>
<abstract>
<p>Worldwide, testing capacity for SARS-CoV-2 is limited and bottlenecks in the scale up of polymerase chain reaction (PCR-based testing exist. Our aim was to develop and evaluate a machine learning algorithm to diagnose COVID-19 in the inpatient setting. The algorithm was based on basic demographic and laboratory features to serve as a screening tool at hospitals where testing is scarce or unavailable. We used retrospectively collected data from the UCLA Health System in Los Angeles, California. We included all emergency room or inpatient cases receiving SARS-CoV-2 PCR testing who also had a set of ancillary laboratory features (n = 1,455) between 1 March 2020 and 24 May 2020. We tested seven machine learning models and used a combination of those models for the final diagnostic classification. In the test set (n = 392), our combined model had an area under the receiver operator curve of 0.91 (95% confidence interval 0.87–0.96). The model achieved a sensitivity of 0.93 (95% CI 0.85–0.98), specificity of 0.64 (95% CI 0.58–0.69). We found that our machine learning algorithm had excellent diagnostic metrics compared to SARS-CoV-2 PCR. This ensemble machine learning algorithm to diagnose COVID-19 has the potential to be used as a screening tool in hospital settings where PCR testing is scarce or unavailable.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>National Institute on Drug Abuse (US)</institution>
</funding-source>
<award-id>K08DA048163</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9382-3564</contrib-id>
<name name-style="western">
<surname>Goodman-Meza</surname>
<given-names>David</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000025</institution-id>
<institution>National Institute of Mental Health</institution>
</institution-wrap>
</funding-source>
<award-id>T32MH080634</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2776-6458</contrib-id>
<name name-style="western">
<surname>Adamson</surname>
<given-names>Paul C.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
<institution>National Institute of Allergy and Infectious Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>K08AI124979</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9895-8636</contrib-id>
<name name-style="western">
<surname>Fulcher</surname>
<given-names>Jennifer A.</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>DGM was supported by the U.S. National Institute on Drug Abuse (K08DA048163, PI Goodman-Meza). PCA was supported by the U.S. National Institute of Mental Health (T32MH080634, PI Currier). JAF was supported by the U.S. National Institute of Allergy and Infectious Disease (K08AI124979, PI Fulcher) and by the Doris Duke Charitable Foundation (Grant 2019086). This project was partially supported by the National Science Foundation (Grant No. 1705197, PI Halperin), and the National Institute of Health (NIH/NHGRI HG010505-02 [PI Halperin], NIH 1R01MH115979 [PI Flint], NIH 5R25GM112625 [PI Eskin], and NIH 5UL1TR001881 [PI Dubinett]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or their employing institutions.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="1"/>
<page-count count="10"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>
The datasets generated during and/or analyzed during the current study are not publicly available due to institutional restrictions on data sharing and privacy concerns. However, the data can be available from the corresponding author on reasonable request. All code necessary to perform the analyses are available from Zenodo:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.4022238" xlink:type="simple">https://doi.org/10.5281/zenodo.4022238</ext-link>
.
</meta-value>
</custom-meta>
<custom-meta id="outbreaks">
<meta-name>Outbreaks</meta-name>
<meta-value>COVID-19</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) is a worldwide public health emergency [
<xref ref-type="bibr" rid="pone.0239474.ref001">1</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref002">2</xref>
]. Polymerase chain reaction (PCR) testing for SARS-CoV-2 is critical to the public health response to coronavirus disease 2019 (COVID-19). PCR testing capacity is especially important in the hospital setting for clinical decision making and infection control procedures [
<xref ref-type="bibr" rid="pone.0239474.ref003">3</xref>
]. Yet, the inability to scale up testing has been one of the most discussed topics in both the scientific and popular literature [
<xref ref-type="bibr" rid="pone.0239474.ref003">3</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref004">4</xref>
].
</p>
<p>
In many hospital settings, PCR testing capacity remains limited. Many PCR assays have short analysis time; however, many hospitals lack on-site PCR capabilities and are tasked with sending samples to centralized laboratories. Transport times and queues lengthen the turnaround time and results can be delayed up to 48 to 96 hours [
<xref ref-type="bibr" rid="pone.0239474.ref005">5</xref>
–
<xref ref-type="bibr" rid="pone.0239474.ref007">7</xref>
]. This wait time slows the clinical decision-making process and wastes scarce personal protective equipment.
</p>
<p>
Machine learning could help fill this gap. Ancillary laboratory values in blood samples of patients with COVID-19 demonstrate a distinct pattern to that of other diseases [
<xref ref-type="bibr" rid="pone.0239474.ref003">3</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref008">8</xref>
–
<xref ref-type="bibr" rid="pone.0239474.ref011">11</xref>
]. These changes include elevations in inflammatory markers (ferritin, lactate dehydrogenase [LDH], C-reactive protein, among others) and decreases in certain blood cell counts (absolute lymphocyte count) and an increase in the neutrophil to lymphocyte ratio. Since the SARS-CoV-2 epidemic reached pandemic status, research groups developed prediction algorithms applicable to their particular context [
<xref ref-type="bibr" rid="pone.0239474.ref012">12</xref>
–
<xref ref-type="bibr" rid="pone.0239474.ref016">16</xref>
]. One of the major limitations of these previous approaches is that the datasets that were used to train and test the approaches were small. Our aim was to develop a machine learning algorithm using the largest dataset to date, to serve as a COVID-19 diagnostic proxy to be useful in hospitals where SARS-CoV-2 specific PCR testing is unavailable or scarce. We hypothesized that a machine learning-based algorithm based on a parsimonious set of blood markers that include inflammatory markers could predict the presence or absence of COVID-19 with high sensitivity and potentially be used as a screening tool in clinical practice.
</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Study design</title>
<p>
We used electronic health data from the UCLA Health System (Los Angeles, California, USA) to develop a machine learning algorithm to serve as a proxy to diagnose COVID-19 in the hospital setting. Our set of features were selected based on prior studies reporting a difference in these features between patients with and without COVID-19, and higher values in those with severe COVID-19 compared to mild COVID-19 [
<xref ref-type="bibr" rid="pone.0239474.ref003">3</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref008">8</xref>
–
<xref ref-type="bibr" rid="pone.0239474.ref011">11</xref>
]. This study was deemed non-human-subjects research by the institutional review board (IRB) at UCLA as all analyses used de-identified data. We report our findings based on STARD-2015 guidelines [
<xref ref-type="bibr" rid="pone.0239474.ref017">17</xref>
].
</p>
</sec>
<sec id="sec004">
<title>Data sources</title>
<p>We retrospectively considered all cases that were tested for SARS-CoV-2 in the emergency room or inpatient setting within the UCLA Health System between 1 March 2020 and 24 May 2020. After constructing our initial pool of cases, we included only cases with complete blood counts and at least one inflammatory marker (C-reactive protein, ferritin, or LDH) within 48 hours of the sample collection for SARS-CoV2 PCR testing.</p>
<p>All data were extracted from the electronic medical record. Features included in the models were age, gender, hemoglobin, red blood cell count, absolute neutrophil, absolute lymphocyte, absolute eosinophil and absolute basophil counts, the neutrophil to lymphocyte ratio, C-reactive protein, ferritin, and LDH. Prior to entering the model, all features were normalized to have zero mean and unit standard deviation. The normalization parameters (e.g., mean and standard deviation) were computed using the training set, and the features in the test set were scaled using these values. After scaling, missing lab values were imputed with zero, effectively inserting the mean feature value from the training set. Mean imputation was determined appropriate after evaluating several imputation methods (K-nearest neighbor and Iterative Imputation), which did not result in significant improvements.</p>
</sec>
<sec id="sec005">
<title>Gold standard</title>
<p>Diagnosis of SARS-CoV-2 was confirmed by PCR testing assays performed at the UCLA Microbiology Laboratory. These assays included the 2019-nCoV Real-Time (RT)-PCR Diagnostic Panel (CDC, Atlanta, GA), the Diasorin Simplexa COVID-19 Direct RT-PCR (Diasorin Molecular LLC, Cypress, CA), the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific Inc., Waltham, MA).</p>
</sec>
<sec id="sec006">
<title>Machine learning analysis</title>
<p>We compared seven machine learning models: Random forest, logistic regression, support vector machine, multilayer perceptron (neural network), stochastic gradient descent, XGBoost, and ADABoost. An ensemble (combined) model was then created based on those seven individually trained machine learning models. The final classification as positive or negative was decided using the majority vote of the classifiers calculated by averaging their respective probabilities. The dataset was split 60% for training, 10% for validation, and 30% for testing. The discriminatory operating threshold was determined using a validation set held out from the training set and selected such that the sensitivity on the validation set would be above a predefined threshold of 0.95 by configuring the beta parameter of the F-score. The resulting model was then evaluated on the held-out test set using the following diagnostic metrics: area under the receiver operator curve (AUROC), area under the precision recall curve (AUPRC), sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). Confidence intervals were constructed for each metric using a bootstrapping procedure on the test set in which the test set was repeatedly resampled with replacement 1000 times. Feature importance was assessed using a permutation test on importance. To test the contribution of each feature to model performance, the feature values were randomly shuffled, thereby disrupting their correlations with the outcome, and the decrease in model performance (f1-score) was recorded. All machine learning analyses were performed using Python, making extensive use of the Scikit-learn package.</p>
</sec>
</sec>
<sec id="sec007" sec-type="results">
<title>Results</title>
<sec id="sec008">
<title>Descriptive</title>
<p>
In total, there were 3,444 cases who were tested for SARS-CoV-2 and considered in our analysis. After exclusion of patients who did not have the minimal necessary features to make predictions (a complete blood cell count and at least one inflammatory marker), 1455 cases remained (1273 negative and 182 positive cases) (see
<xref ref-type="fig" rid="pone.0239474.g001">Fig 1</xref>
). All cases were either from the emergency room or inpatient settings. Mean age was 58.1 (SD 22.3), 53% were men, 49% white, 24% Latino, and 29% immunosuppressed. See
<xref ref-type="table" rid="pone.0239474.t001">Table 1</xref>
for descriptive characteristics for included features by SARS-CoV-2 status.
</p>
<fig id="pone.0239474.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0239474.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Diagram of eligible, included and excluded cases, and diagnostic cross tabulation.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0239474.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0239474.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0239474.t001</object-id>
<label>Table 1</label>
<caption>
<title>Characteristics of cases by SARS-CoV-2 status.</title>
</caption>
<alternatives>
<graphic id="pone.0239474.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0239474.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" style="background-color:#FFFFFF"/>
<th align="center" colspan="2" style="background-color:#FFFFFF">SARS-CoV-2 status</th>
<th align="center" style="background-color:#FFFFFF"/>
<th align="center" style="background-color:#FFFFFF"/>
</tr>
<tr>
<th align="left" style="background-color:#FFFFFF"/>
<th align="center" style="background-color:#FFFFFF">
Negative
<break/>
n (%)
</th>
<th align="center" style="background-color:#FFFFFF">
Positive
<break/>
n (%)
</th>
<th align="center" style="background-color:#FFFFFF">
Total
<break/>
n
</th>
<th align="center" style="background-color:#FFFFFF">p- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" style="background-color:#F9F9F9">Total</td>
<td align="center" style="background-color:#F9F9F9">1273 (87.5)</td>
<td align="center" style="background-color:#F9F9F9">182 (12.5)</td>
<td align="center" style="background-color:#F9F9F9">1455</td>
<td align="center" style="background-color:#F9F9F9"/>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">Age, years, mean (SD)</td>
<td align="center" style="background-color:#F9F9F9">57.2 (22.6)</td>
<td align="center" style="background-color:#F9F9F9">64.2 (19.1)</td>
<td align="center" style="background-color:#F9F9F9">58.1 (22.3)</td>
<td align="center" style="background-color:#F9F9F9"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Gender</td>
<td align="center" style="background-color:#FFFFFF"/>
<td align="center" style="background-color:#FFFFFF"/>
<td align="center" style="background-color:#FFFFFF"/>
<td align="center" style="background-color:#FFFFFF">0.030</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">    Female</td>
<td align="center" style="background-color:#FFFFFF">610 (47.9)</td>
<td align="center" style="background-color:#FFFFFF">71 (39.0)</td>
<td align="center" style="background-color:#FFFFFF">681 (46.8)</td>
<td align="center" style="background-color:#FFFFFF"/>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">    Male</td>
<td align="center" style="background-color:#F9F9F9">663 (52.1)</td>
<td align="center" style="background-color:#F9F9F9">111 (61.0)</td>
<td align="center" style="background-color:#F9F9F9">774 (53.2)</td>
<td align="center" style="background-color:#F9F9F9"/>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Race/ethnicity</td>
<td align="center" style="background-color:#FFFFFF"/>
<td align="center" style="background-color:#FFFFFF"/>
<td align="center" style="background-color:#FFFFFF"/>
<td align="center" style="background-color:#FFFFFF">0.006</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">    Asian</td>
<td align="center" style="background-color:#FFFFFF">91 (7.1)</td>
<td align="center" style="background-color:#FFFFFF">16 (8.8)</td>
<td align="center" style="background-color:#FFFFFF">107 (7.4)</td>
<td align="center" style="background-color:#FFFFFF"/>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">    Black</td>
<td align="center" style="background-color:#FFFFFF">156 (12.3)</td>
<td align="center" style="background-color:#FFFFFF">18 (9.9)</td>
<td align="center" style="background-color:#FFFFFF">174 (12.0)</td>
<td align="center" style="background-color:#FFFFFF"/>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">    Latino</td>
<td align="center" style="background-color:#F9F9F9">281 (22.1)</td>
<td align="center" style="background-color:#F9F9F9">61 (33.5)</td>
<td align="center" style="background-color:#F9F9F9">342 (23.5)</td>
<td align="center" style="background-color:#F9F9F9"/>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">    Other</td>
<td align="center" style="background-color:#FFFFFF">110 (8.6)</td>
<td align="center" style="background-color:#FFFFFF">17 (9.3)</td>
<td align="center" style="background-color:#FFFFFF">127 (8.7)</td>
<td align="center" style="background-color:#FFFFFF"/>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">    White</td>
<td align="center" style="background-color:#F9F9F9">635 (49.9)</td>
<td align="center" style="background-color:#F9F9F9">70 (38.5)</td>
<td align="center" style="background-color:#F9F9F9">705 (48.5)</td>
<td align="center" style="background-color:#F9F9F9"/>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">
Immunosuppressed
<sup>+</sup>
</td>
<td align="center" style="background-color:#F9F9F9">385 (30.2)</td>
<td align="center" style="background-color:#F9F9F9">35 (19.2)</td>
<td align="center" style="background-color:#F9F9F9">420 (28.9)</td>
<td align="center" style="background-color:#F9F9F9">0.003</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">    HIV</td>
<td align="center" style="background-color:#F9F9F9">17 (1.3)</td>
<td align="center" style="background-color:#F9F9F9">1 (0.5)</td>
<td align="center" style="background-color:#F9F9F9">18 (1.2)</td>
<td align="center" style="background-color:#F9F9F9">0.590</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">    Transplant</td>
<td align="center" style="background-color:#F9F9F9">180 (14.1)</td>
<td align="center" style="background-color:#F9F9F9">19 (10.4)</td>
<td align="center" style="background-color:#F9F9F9">199 (13.7)</td>
<td align="center" style="background-color:#F9F9F9">0.214</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">    Immunosuppressive medications</td>
<td align="center" style="background-color:#F9F9F9">312 (24.5)</td>
<td align="center" style="background-color:#F9F9F9">29 (15.9)</td>
<td align="center" style="background-color:#F9F9F9">341 (23.4)</td>
<td align="center" style="background-color:#F9F9F9">0.014</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">Not immunosuppressed</td>
<td align="center" style="background-color:#F9F9F9">888 (69.8)</td>
<td align="center" style="background-color:#F9F9F9">147 (80.8)</td>
<td align="center" style="background-color:#F9F9F9">1035 (71.1)</td>
<td align="center" style="background-color:#F9F9F9"/>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">
Hemoglobin, g/dl, mean (SD)
<sup>a</sup>
</td>
<td align="center" style="background-color:#FFFFFF">
11.80
<break/>
(9.90–13.5)
</td>
<td align="center" style="background-color:#FFFFFF">
12.60
<break/>
(11.0–14.2)
</td>
<td align="center" style="background-color:#FFFFFF">
11.90
<break/>
(10.0–13.6)
</td>
<td align="center" style="background-color:#FFFFFF"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">Absolute neutrophil count x 10^3/uL, median (IQR)</td>
<td align="center" style="background-color:#F9F9F9">
6.02
<break/>
(3.93–9.39)
</td>
<td align="center" style="background-color:#F9F9F9">
5.19
<break/>
(3.47–7.46)
</td>
<td align="center" style="background-color:#F9F9F9">
5.92
<break/>
(3.88–9.12)
</td>
<td align="center" style="background-color:#F9F9F9">0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">
Absolute lymphocyte count x 10^3/uL, median (IQR)
<sup>e</sup>
</td>
<td align="center" style="background-color:#FFFFFF">
1.22
<break/>
(0.74–1.90)
</td>
<td align="center" style="background-color:#FFFFFF">
0.96
<break/>
(0.63–1.38)
</td>
<td align="center" style="background-color:#FFFFFF">
1.18
<break/>
(0.72–1.86)
</td>
<td align="center" style="background-color:#FFFFFF"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">Neutrophil:lymphocyte ratio, median (IQR)</td>
<td align="center" style="background-color:#F9F9F9">
4.81
<break/>
(2.47–9.77)
</td>
<td align="center" style="background-color:#F9F9F9">
5.21
<break/>
(2.91–10.3)
</td>
<td align="center" style="background-color:#F9F9F9">
4.88
<break/>
(2.56–9.81)
</td>
<td align="center" style="background-color:#F9F9F9">0.112</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Absolute basophil count x 10^3/uL, median (IQR)</td>
<td align="center" style="background-color:#FFFFFF">
0.03
<break/>
(0.02–0.05)
</td>
<td align="center" style="background-color:#FFFFFF">
0.01
<break/>
(0.01–0.03)
</td>
<td align="center" style="background-color:#FFFFFF">
0.03
<break/>
(0.02–0.05)
</td>
<td align="center" style="background-color:#FFFFFF"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">Absolute eosinophil count x 10^3/uL, median (IQR)</td>
<td align="center" style="background-color:#F9F9F9">
0.08
<break/>
(0.02–0.18)
</td>
<td align="center" style="background-color:#F9F9F9">
0.01
<break/>
(0.00–0.04)
</td>
<td align="center" style="background-color:#F9F9F9">
0.07
<break/>
(0.01–0.16)
</td>
<td align="center" style="background-color:#F9F9F9"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Absolute monocyte count x 10^3/uL, median (IQR)</td>
<td align="center" style="background-color:#FFFFFF">
0.65
<break/>
(0.47–0.95)
</td>
<td align="center" style="background-color:#FFFFFF">
0.48
<break/>
(0.33–0.70)
</td>
<td align="center" style="background-color:#FFFFFF">
0.64
<break/>
(0.44–0.92)
</td>
<td align="center" style="background-color:#FFFFFF"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">
Platelet count x 10^3/uL, mean (SD)
<sup>b</sup>
</td>
<td align="center" style="background-color:#F9F9F9">
231
<break/>
(168–298)
</td>
<td align="center" style="background-color:#F9F9F9">
188
<break/>
(149–252)
</td>
<td align="center" style="background-color:#F9F9F9">
227
<break/>
(164–291)
</td>
<td align="center" style="background-color:#F9F9F9"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">
C-reactive protein, mg/dl, mean (SD)
<sup>c</sup>
</td>
<td align="center" style="background-color:#FFFFFF">
1.90
<break/>
(0.30–7.80)
</td>
<td align="center" style="background-color:#FFFFFF">
6.60
<break/>
(2.10–12.2)
</td>
<td align="center" style="background-color:#FFFFFF">
2.80
<break/>
(0.50–8.90)
</td>
<td align="center" style="background-color:#FFFFFF"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">
Ferritin, ng/ml, mean (SD)
<sup>d</sup>
</td>
<td align="center" style="background-color:#FFFFFF">
216
<break/>
(93.0–522)
</td>
<td align="center" style="background-color:#FFFFFF">
439
<break/>
(261–770)
</td>
<td align="center" style="background-color:#FFFFFF">
261
<break/>
(110–585)
</td>
<td align="center" style="background-color:#FFFFFF"><0.001</td>
</tr>
<tr>
<td align="left" style="background-color:#F9F9F9">
Lactate dehydrogenase, U/L, mean (SD)
<sup>e</sup>
</td>
<td align="center" style="background-color:#F9F9F9">
245
<break/>
(192–342)
</td>
<td align="center" style="background-color:#F9F9F9">
306
<break/>
(231–412)
</td>
<td align="center" style="background-color:#F9F9F9">
261
<break/>
(198–357)
</td>
<td align="center" style="background-color:#F9F9F9"><0.001</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p>
<bold>Abbreviations:</bold>
IQR, interquartile range; SD, standard deviation.
</p>
</fn>
<fn id="t001fn002">
<p>
<bold>Missing values (n, % of total):</bold>
<sup>a</sup>
hemoglobin 3 (0.2%);
<sup>b</sup>
platelets 6 (0.4%);
<sup>c</sup>
C-reactive protein 517 (35.5%);
<sup>d</sup>
ferritin 737 (50.6%);
<sup>e</sup>
lactate dehydrogenase 693 (47.6%).
</p>
</fn>
<fn id="t001fn003">
<p>
<sup>+</sup>
We defined immunosuppressed status as a case with an HIV diagnosis, record of receipt of an organ transplant, or had taken an oral immunosuppressive medication prior to their SARS-CoV-2 test (e.g., prednisone, tacrolimus, mycophenolate, azathioprine, methotrexate).
</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec009">
<title>Machine learning model: Diagnostic metrics</title>
<p>
The AUROC of the model in the held-out test set (n = 392) was 0.91 (95% confidence interval [CI] 0.87–0.96) and the AUPRC was 0.76 (95% CI 0.66–0.83). The model achieved a sensitivity of 0.93 (95% CI 0.84–0.98), specificity of 0.64 (95% CI 0.59–0.69), NPV of 0.98 (95% CI 0.96–1.00), and PPV of 0.29 (95% CI 0.23–0.36). Receiver operator curves and precision-recall curves were presented in
<xref ref-type="fig" rid="pone.0239474.g002">Fig 2</xref>
. Using a feature importance analysis, we found that the features that provide most of the information to the model were: C-reactive protein and LDH (see
<xref ref-type="fig" rid="pone.0239474.g003">Fig 3</xref>
).
</p>
<fig id="pone.0239474.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0239474.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Performance of the model on the held-out test set (N = 392).</title>
<p>A) Receiver operator curve. B) Precision-recall curve. At a sensitivity-optimized operating threshold, sensitivity and specificity were 0.93 (95% CI 0.85–0.98) and 0.64 (95% CI 0.59–0.69), respectively. Red solid lines were the mean receiver operator curve and mean precision-recall curve, respectively; the purple shaded lines were the curves obtained from the bootstrapping procedure to calculate the 95% confidence intervals.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0239474.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0239474.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0239474.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Combined model feature importance.</title>
<p>Decrease in model performance (f1-score) after randomly shuffling the respective feature values. Higher values represent important features for classification. Abbreviations: LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; RBC, red blood cells.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0239474.g003" xlink:type="simple"/>
</fig>
<p>
In sensitivity analyses, we calculated AUROC and AUPRC when adding the inflammatory features relative to the baseline model of only demographic characteristics and features of the complete blood cell count (see
<xref ref-type="fig" rid="pone.0239474.g004">Fig 4</xref>
). The AUROC of the model of the baseline model was 0.79 (95% CI 0.71–0.85). Then, we added the inflammatory markers to the model one at a time. With ferritin, the AUROC was 0.83 (95% CI 0.78–0.88); with C-reactive protein 0.86 (95% CI 0.79–0.92); with LDH, 0.87 (95% CI 0.82–0.92). The AUPRC of the baseline model was 0.50 (95% CI 0.36–0.65); with ferritin 0.56 (95% CI 0.45–0.68); with LDH, 0.66 (95% CI 0.55–0.77); with C-reactive protein 0.66 (95% CI 0.50–0.80). Through these analyses we observed that adding inflammatory markers, especially LDH, CRP, and the combination of the three resulted in statistically significant improvements relative to the baseline model.
</p>
<fig id="pone.0239474.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0239474.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Performance of models while removing one of the features.</title>
<p>All analyses were performed on the held-out test set (N = 392). A) Receiver operating curve. B) Precision-recall curve. Base model includes only demographic features and complete blood cell count. Abbreviations: CRP, C-reactive protein; LDH, lactate dehydrogenase.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0239474.g004" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec010" sec-type="conclusions">
<title>Discussion</title>
<p>This is the largest study to date using a machine learning algorithm as a proxy to diagnose COVID-19. We built the algorithm based on a set of basic demographic characteristics and frequently obtained blood biomarkers that could be easily obtained in many hospital settings. Thus, the most likely application of the approach presented in this work is the use of these biomarkers as a proxy for testing in locations where COVID-19 testing is scarce. We showed a high sensitivity for COVID-19 diagnosis when compared to SARS-CoV-2 RT PCR testing as the gold standard. The blood biomarkers included in the model can be obtained with a single blood draw and turnaround time is typically within 24 hours at most hospital centers with laboratory capabilities. Due to the model’s high sensitivity and rapid turnaround time, the proposed algorithm lends itself to practical use in hospital facilities as a screening tool. At the time of submission, this model was being actively developed into a web or mobile application, whereby a clinician inputs the obtained values and receives immediate prediction on the probability of a particular patient having COVID-19. Further validation will be required to ascertain its performance in other medical centers.</p>
<p>
Our set of features performed as well as, or better than, the three diagnostic algorithms with the largest number of cases known to us at this time [
<xref ref-type="bibr" rid="pone.0239474.ref012">12</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref013">13</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref016">16</xref>
]. A report by Sun et al. used epidemiologic, clinical, laboratory and imaging features in their algorithms and reported AUROCs of 0.91 (full model), 0.88 (without epidemiologic features), 0.88 (without imaging features), and 0.65 (with clinical features alone) [
<xref ref-type="bibr" rid="pone.0239474.ref012">12</xref>
]. They used features from a complete blood cell count and from a basic chemistry panel (sodium and creatinine), whereas, we used inflammatory markers (ferritin, C-reactive protein, LDH) instead of sodium, potassium, and creatinine as we did not suspect significant differences
<italic>a priori</italic>
in sodium, potassium, or creatinine. Meng et al reported an AUROC of 0.89 using a different set of features that included activated partial thromboplastin time, triglycerides, uric acid, albumin/globulin, sodium, and calcium [
<xref ref-type="bibr" rid="pone.0239474.ref016">16</xref>
]. Batista et al. developed an algorithm aimed for use in lower resource settings and reported an AUROC of 0.87 in a sparser dataset that only included basic demographics and complete blood cell counts [
<xref ref-type="bibr" rid="pone.0239474.ref013">13</xref>
]. In fact, our model which incorporated inflammatory markers significantly improved upon this set of features in terms of both AUROC and AUPRC. For a full comparison of diagnostic algorithms related to COVID-19 we refer the reader to [
<xref ref-type="bibr" rid="pone.0239474.ref015">15</xref>
]—a living systematic review.
</p>
<p>
Our findings should be considered in light of the following limitations. We included data from one medical center in Los Angeles. Incorporating data from other medical centers in other geographic areas would provide a higher likelihood of generalizability. Second, although many of our patients either had immunosuppressive conditions (e.g., solid organ transplants) or were taking immunosuppressive medications (e.g., steroids), immunosuppressed hosts are a heterogenous group and their immunosuppression may impact the laboratory values we used in our models. We would need more cases with those conditions to understand how the algorithm would perform in these populations. It is likely that specific models tailored to the immunocompromised host should be developed to improve accuracy in this population. Third, it is also possible that other community respiratory viral infections (e.g., influenza, RSV) could cause a similar laboratory profile; however, incidence of these other community respiratory viruses was low during the case inclusion period. Further validation comparing COVID-19 cases to cases of other community respiratory viruses is needed. Finally, as all of our patients’ blood was tested in the emergency department or as an inpatient, the applicability of this model in the outpatient setting or milder cases of COVID-19 is unclear.Our report, in combination with others [
<xref ref-type="bibr" rid="pone.0239474.ref012">12</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref013">13</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref015">15</xref>
,
<xref ref-type="bibr" rid="pone.0239474.ref016">16</xref>
], demonstrate the high diagnostic accuracy of machine learning models based on early available data. Other models have also been developed based on characteristic imaging changes [
<xref ref-type="bibr" rid="pone.0239474.ref015">15</xref>
]. We and others were able to demonstrate impressive results in our data silos [
<xref ref-type="bibr" rid="pone.0239474.ref012">12</xref>
–
<xref ref-type="bibr" rid="pone.0239474.ref015">15</xref>
]. Yet, to realize the full potential of machine learning and its applicability to clinical medicine, collaborations from the international community are crucial, both for the sharing of data and for the development and validation of advanced algorithms. It is unclear if testing capacity for active disease using PCR-based methods will ever meet the expanding need globally. In fact, countries in low-resource settings, such as in Sub-Saharan Africa or Latin America, face bottlenecks in the testing supply chain, and are unable to compete with affluent nations for prohibitively expensive PCR test kits. Even in developed nations, scale up of PCR-based testing has many bottlenecks that include purchase of new testing platforms, sample acquisition, availability of reagents, swabs and transport media, and the technical human expertise in performing PCR tests.
</p>
<p>In summary, by using readily available laboratory tests combined with machine learning we achieved a high sensitivity comparable to that of PCR. This machine learning modality may be especially useful as a screening test in smaller medical centers or those in resource-poor regions that may have limited capacity for COVID-19 PCR-based diagnosis, or in instances were testing capacity is in danger due to low supplies. Further validation is necessary in diverse geographic settings and in a prospective manor to be used is a reliable tool to support clinical decision making.</p>
</sec>
<sec id="sec011">
<title>Supporting information</title>
<supplementary-material id="pone.0239474.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0239474.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title/>
<p>(PDF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0239474.ref001">
<label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Team</surname>
<given-names>CC-R</given-names>
</name>
.
<article-title>Geographic Differences in COVID-19 Cases, Deaths, and Incidence—United States, February 12-April 7, 2020</article-title>
.
<source>MMWR Morb Mortal Wkly Rep</source>
.
<year>2020</year>
;
<volume>69</volume>
(
<issue>15</issue>
):
<fpage>465</fpage>
–
<lpage>71</lpage>
. Epub 2020/04/17.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.15585/mmwr.mm6915e4" xlink:type="simple">10.15585/mmwr.mm6915e4</ext-link>
</comment>
<object-id pub-id-type="pmid">32298250</object-id>
.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref002">
<label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Dong</surname>
<given-names>E</given-names>
</name>
,
<name name-style="western">
<surname>Du</surname>
<given-names>H</given-names>
</name>
,
<name name-style="western">
<surname>Gardner</surname>
<given-names>L</given-names>
</name>
.
<article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title>
.
<source>Lancet Infect Dis</source>
.
<year>2020</year>
. Epub 2020/02/23.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s1473-3099%2820%2930120-1" xlink:type="simple">10.1016/s1473-3099(20)30120-1</ext-link>
</comment>
<object-id pub-id-type="pmid">32087114</object-id>
; PubMed Central PMCID: PMC7159018.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref003">
<label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Cheng</surname>
<given-names>MP</given-names>
</name>
,
<name name-style="western">
<surname>Papenburg</surname>
<given-names>J</given-names>
</name>
,
<name name-style="western">
<surname>Desjardins</surname>
<given-names>M</given-names>
</name>
,
<name name-style="western">
<surname>Kanjilal</surname>
<given-names>S</given-names>
</name>
,
<name name-style="western">
<surname>Quach</surname>
<given-names>C</given-names>
</name>
,
<name name-style="western">
<surname>Libman</surname>
<given-names>M</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2</article-title>
.
<source>Annals of Internal Medicine</source>
.
<year>2020</year>
;
<volume>172</volume>
(
<issue>11</issue>
):
<fpage>726</fpage>
–
<lpage>34</lpage>
.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7326/M20-1301" xlink:type="simple">10.7326/M20-1301</ext-link>
</comment>
<object-id pub-id-type="pmid">32282894</object-id>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref004">
<label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Cheng</surname>
<given-names>MP</given-names>
</name>
,
<name name-style="western">
<surname>Papenburg</surname>
<given-names>J</given-names>
</name>
,
<name name-style="western">
<surname>Desjardins</surname>
<given-names>M</given-names>
</name>
,
<name name-style="western">
<surname>Kanjilal</surname>
<given-names>S</given-names>
</name>
,
<name name-style="western">
<surname>Quach</surname>
<given-names>C</given-names>
</name>
,
<name name-style="western">
<surname>Libman</surname>
<given-names>M</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review</article-title>
.
<source>Ann Intern Med</source>
.
<year>2020</year>
.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7326/m20-1301" xlink:type="simple">10.7326/m20-1301</ext-link>
</comment>
<object-id pub-id-type="pmid">32282894</object-id>
; PubMed Central PMCID: PMC7170415.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref005">
<label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Ward</surname>
<given-names>S</given-names>
</name>
,
<name name-style="western">
<surname>Lindsley</surname>
<given-names>A</given-names>
</name>
,
<name name-style="western">
<surname>Courter</surname>
<given-names>J</given-names>
</name>
,
<name name-style="western">
<surname>Assa'ad</surname>
<given-names>A</given-names>
</name>
.
<article-title>Clinical Testing For Covid-19</article-title>
.
<source>J Allergy Clin Immunol</source>
.
<year>2020</year>
. Epub 2020/05/24.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jaci.2020.05.012" xlink:type="simple">10.1016/j.jaci.2020.05.012</ext-link>
</comment>
<object-id pub-id-type="pmid">32445839</object-id>
; PubMed Central PMCID: PMC7237919.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref006">
<label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Sheridan</surname>
<given-names>C</given-names>
</name>
.
<article-title>Coronavirus and the race to distribute reliable diagnostics</article-title>
.
<source>Nature Biotechnology</source>
.
<year>2020</year>
;
<volume>38</volume>
(
<issue>4</issue>
):
<fpage>382</fpage>
–
<lpage>4</lpage>
.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/d41587-020-00002-2" xlink:type="simple">10.1038/d41587-020-00002-2</ext-link>
</comment>
<object-id pub-id-type="pmid">32265548</object-id>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref007">
<label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Service</surname>
<given-names>R.</given-names>
</name>
<article-title>The standard coronavirus test, if available, works well—but can new diagnostics help in this pandemic?</article-title>
<source>Science</source>
.
<year>2020</year>
.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.abb8400" xlink:type="simple">10.1126/science.abb8400</ext-link>
</comment>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref008">
<label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Zhou</surname>
<given-names>F</given-names>
</name>
,
<name name-style="western">
<surname>Yu</surname>
<given-names>T</given-names>
</name>
,
<name name-style="western">
<surname>Du</surname>
<given-names>R</given-names>
</name>
,
<name name-style="western">
<surname>Fan</surname>
<given-names>G</given-names>
</name>
,
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
,
<name name-style="western">
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>
.
<source>Lancet</source>
.
<year>2020</year>
;
<volume>395</volume>
(
<issue>10229</issue>
):
<fpage>1054</fpage>
–
<lpage>62</lpage>
. Epub 2020/03/15.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736%2820%2930566-3" xlink:type="simple">10.1016/S0140-6736(20)30566-3</ext-link>
</comment>
<object-id pub-id-type="pmid">32171076</object-id>
.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref009">
<label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>D</given-names>
</name>
,
<name name-style="western">
<surname>Hu</surname>
<given-names>B</given-names>
</name>
,
<name name-style="western">
<surname>Hu</surname>
<given-names>C</given-names>
</name>
,
<name name-style="western">
<surname>Zhu</surname>
<given-names>F</given-names>
</name>
,
<name name-style="western">
<surname>Liu</surname>
<given-names>X</given-names>
</name>
,
<name name-style="western">
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title>
.
<source>JAMA</source>
.
<year>2020</year>
.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2020.1585" xlink:type="simple">10.1001/jama.2020.1585</ext-link>
</comment>
<object-id pub-id-type="pmid">32031570</object-id>
; PubMed Central PMCID: PMC7042881.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref010">
<label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Guan</surname>
<given-names>WJ</given-names>
</name>
,
<name name-style="western">
<surname>Ni</surname>
<given-names>ZY</given-names>
</name>
,
<name name-style="western">
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
,
<name name-style="western">
<surname>Liang</surname>
<given-names>WH</given-names>
</name>
,
<name name-style="western">
<surname>Ou</surname>
<given-names>CQ</given-names>
</name>
,
<name name-style="western">
<surname>He</surname>
<given-names>JX</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>
.
<source>N Engl J Med</source>
.
<year>2020</year>
;
<volume>382</volume>
(
<issue>18</issue>
):
<fpage>1708</fpage>
–
<lpage>20</lpage>
. Epub 2020/02/29.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa2002032" xlink:type="simple">10.1056/NEJMoa2002032</ext-link>
</comment>
<object-id pub-id-type="pmid">32109013</object-id>
; PubMed Central PMCID: PMC7092819.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref011">
<label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Petrilli</surname>
<given-names>CM</given-names>
</name>
,
<name name-style="western">
<surname>Jones</surname>
<given-names>SA</given-names>
</name>
,
<name name-style="western">
<surname>Yang</surname>
<given-names>J</given-names>
</name>
,
<name name-style="western">
<surname>Rajagopalan</surname>
<given-names>H</given-names>
</name>
,
<name name-style="western">
<surname>O'Donnell</surname>
<given-names>LF</given-names>
</name>
,
<name name-style="western">
<surname>Chernyak</surname>
<given-names>Y</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City.</article-title>
<source>medRxiv</source>
.
<year>2020</year>
:2020.04.08.20057794.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2020.04.08.20057794" xlink:type="simple">10.1101/2020.04.08.20057794</ext-link>
</comment>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref012">
<label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
,
<name name-style="western">
<surname>Koh</surname>
<given-names>V</given-names>
</name>
,
<name name-style="western">
<surname>Marimuthu</surname>
<given-names>K</given-names>
</name>
,
<name name-style="western">
<surname>Ng</surname>
<given-names>OT</given-names>
</name>
,
<name name-style="western">
<surname>Young</surname>
<given-names>B</given-names>
</name>
,
<name name-style="western">
<surname>Vasoo</surname>
<given-names>S</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Epidemiological and Clinical Predictors of COVID-19</article-title>
.
<source>Clin Infect Dis</source>
.
<year>2020</year>
. Epub 2020/03/27.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciaa322" xlink:type="simple">10.1093/cid/ciaa322</ext-link>
</comment>
<object-id pub-id-type="pmid">32211755</object-id>
.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref013">
<label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Batista</surname>
<given-names>AFdM</given-names>
</name>
,
<name name-style="western">
<surname>Miraglia</surname>
<given-names>JL</given-names>
</name>
,
<name name-style="western">
<surname>Donato</surname>
<given-names>THR</given-names>
</name>
,
<name name-style="western">
<surname>Chiavegatto Filho</surname>
<given-names>ADP</given-names>
</name>
.
<article-title>COVID-19 diagnosis prediction in emergency care patients: a machine learning approach</article-title>
.
<source>medRxiv</source>
.
<year>2020</year>
:2020.04.04.20052092.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2020.04.04.20052092" xlink:type="simple">10.1101/2020.04.04.20052092</ext-link>
</comment>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref014">
<label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Feng CH</surname>
<given-names>Zhi</given-names>
</name>
;
<name name-style="western">
<surname>Wang</surname>
<given-names>Lili</given-names>
</name>
;
<name name-style="western">
<surname>Chen</surname>
<given-names>Xin</given-names>
</name>
;
<name name-style="western">
<surname>Zhai</surname>
<given-names>Yongzhi</given-names>
</name>
;
<name name-style="western">
<surname>Zhu</surname>
<given-names>Feng</given-names>
</name>
;
<name name-style="western">
<surname>Chen</surname>
<given-names>Hua</given-names>
</name>
;
<etal>et al</etal>
.
<article-title>A Novel Triage Tool of Artificial Intelligence Assisted Diagnosis Aid System for Suspected COVID-19 Pneumonia in Fever Clinics</article-title>
.
<source>SSRN</source>
.
<year>2020</year>
. Epub 3/8/2020.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/dx.doi.org/10.2139/ssrn.3551355" xlink:type="simple">dx.doi.org/10.2139/ssrn.3551355</ext-link>
</comment>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref015">
<label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Wynants</surname>
<given-names>L</given-names>
</name>
,
<name name-style="western">
<surname>Van Calster</surname>
<given-names>B</given-names>
</name>
,
<name name-style="western">
<surname>Bonten</surname>
<given-names>MMJ</given-names>
</name>
,
<name name-style="western">
<surname>Collins</surname>
<given-names>GS</given-names>
</name>
,
<name name-style="western">
<surname>Debray</surname>
<given-names>TPA</given-names>
</name>
,
<name name-style="western">
<surname>De Vos</surname>
<given-names>M</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal</article-title>
.
<source>Bmj</source>
.
<year>2020</year>
;
<volume>369</volume>
:
<fpage>m1328</fpage>
. Epub 2020/04/09.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.m1328" xlink:type="simple">10.1136/bmj.m1328</ext-link>
</comment>
<object-id pub-id-type="pmid">32265220</object-id>
.
</mixed-citation>
</ref>
<ref id="pone.0239474.ref016">
<label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Meng</surname>
<given-names>Z</given-names>
</name>
,
<name name-style="western">
<surname>Wang</surname>
<given-names>M</given-names>
</name>
,
<name name-style="western">
<surname>Song</surname>
<given-names>H</given-names>
</name>
,
<name name-style="western">
<surname>Guo</surname>
<given-names>S</given-names>
</name>
,
<name name-style="western">
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
,
<name name-style="western">
<surname>Li</surname>
<given-names>W</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>Development and utilization of an intelligent application for aiding COVID-19 diagnosis</article-title>
.
<source>medRxiv</source>
.
<year>2020</year>
:2020.03.18.20035816.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2020.03.18.20035816" xlink:type="simple">10.1101/2020.03.18.20035816</ext-link>
</comment>
</mixed-citation>
</ref>
<ref id="pone.0239474.ref017">
<label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western">
<surname>Bossuyt</surname>
<given-names>PM</given-names>
</name>
,
<name name-style="western">
<surname>Reitsma</surname>
<given-names>JB</given-names>
</name>
,
<name name-style="western">
<surname>Bruns</surname>
<given-names>DE</given-names>
</name>
,
<name name-style="western">
<surname>Gatsonis</surname>
<given-names>CA</given-names>
</name>
,
<name name-style="western">
<surname>Glasziou</surname>
<given-names>PP</given-names>
</name>
,
<name name-style="western">
<surname>Irwig</surname>
<given-names>L</given-names>
</name>
,
<etal>et al</etal>
.
<article-title>STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies</article-title>
.
<source>Bmj</source>
.
<year>2015</year>
;
<volume>351</volume>
:
<fpage>h5527</fpage>
. Epub 2015/10/30.
<comment>
doi:
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.h5527" xlink:type="simple">10.1136/bmj.h5527</ext-link>
</comment>
<object-id pub-id-type="pmid">26511519</object-id>
; PubMed Central PMCID: PMC4623764
</mixed-citation>
</ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0239474.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0239474.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Urbanowicz</surname>
<given-names>Ryan J.</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Ryan J. Urbanowicz</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>
This is an open access article distributed under the terms of the
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0239474" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<boxed-text id="pone-0239474-box001" position="float" specific-use="prior_peer_review_unavailable">
<sec id="sec012">
<title>Transfer Alert</title>
<p>This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.</p>
</sec>
</boxed-text>
<p>
<named-content content-type="letter-date">8 Sep 2020</named-content>
</p>
<p>A m achine learning algorithm to increase COVID-19 inpatient diagnostic capacity</p>
<p>PONE-D-20-20126</p>
<p>Dear Dr. Goodman-Meza,</p>
<p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
<p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
<p>
An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at
<ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/" xlink:type="simple">http://www.editorialmanager.com/pone/</ext-link>
, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at
<email xlink:type="simple">authorbilling@plos.org</email>
.
</p>
<p>
If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact
<email xlink:type="simple">onepress@plos.org</email>
.
</p>
<p>Kind regards,</p>
<p>Ryan J. Urbanowicz, Ph.D.</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p>
<!--  <font color="black">  -->
<bold>Comments to the Author</bold>
</p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>
The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
<!--  </font>  -->
</p>
<p>Reviewer #1: Partly</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>
<!--  <font color="black">  -->
2. Has the statistical analysis been performed appropriately and rigorously?
<!--  </font>  -->
</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>
<!--  <font color="black">  -->
3. Have the authors made all data underlying the findings in their manuscript fully available?
</p>
<p>
The
<ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link>
requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.
<!--  </font>  -->
</p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>
<!--  <font color="black">  -->
4. Is the manuscript presented in an intelligible fashion and written in standard English?
</p>
<p>
PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
<!--  </font>  -->
</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>
<!--  <font color="black">  -->
5. Review Comments to the Author
</p>
<p>
Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
<!--  </font>  -->
</p>
<p>Reviewer #1: * Yes, the manuscript is technically sound. The only reason I said "Partly" to question 1 above is that for reasons out of the authors' control, the sample size is somewhat small. However, as they say, there is the (very exciting) prospect that such work can lead to data-sharing, particularly among hospitals in diverse regions for data-diversity, leading to much larger training data-sets and hence, more-accurate models for realistic data.</p>
<p>* The statistical analysis is rigorous.</p>
<p>* The answer to question 3 is "No" since the data is anonymized medical-center data: the authors say "The datasets generated during and/or analyzed during the current study are not publicly available due to institutional restrictions on data sharing and privacy concerns. However, the data can be available from the corresponding author on reasonable request. All code necessary to perform the analyses will be available on a public repository by the time of publication." I think this is reasonable, and really the best that can be expected under the circumstances.</p>
<p>* The paper is well-written in general, but I have one technical question (see (e) below) and a few minor comments:</p>
<p>(a) Page 9: "pandemic status research" -> pandemic status, research"</p>
<p>(b) Hyphenate multi-word adjectives throughout: e.g., as in "machine-learning algorithm"</p>
<p>(c) Page 10: "from UCLA Health System" -> "from the UCLA Health System"</p>
<p>(d) Page 10: "non-human subjects" -> "non-human-subjects"</p>
<p>(e) Page 10, on normalizing all features: How do you do such normalization for gender -- a discrete feature with very small support?</p>
<p>Reviewer #2: The paper by Goodman-Meza et al. describes an ensemble machine learning algorithm for the diagnosis of COVID-19. Specifically, using the largest available dataset of patients testing for COVID-19 in the hospital setting, the authors make use of demographic and laboratory features to obtain highly accurate predictions. Their results are comparable to the gold-standard PCR test. This work is particularly valuable for COVID-19 diagnosis at hospitals with limited resources or where standard testing is too slow. Despite the limitation of generalizability, overall this research provides a useful model for the diagnosis of COVID-19 in the hospital setting.</p>
<p>Patients were excluded from the analysis if they did not have a CBC and at least one inflammatory lab value. Patients who tested positive for COVID-19 were more likely to be older, male, and not immunosuppressed. Drawing upon recent literature, the authors chose age, gender, seven features from blood cell counts, and three inflammatory markers as features for their model. Missing data was imputed post-normalization using the mean values.</p>
<p>Using seven machine learning models, the authors created an ensemble machine learning algorithm which classified patients as positive or negative using a majority vote. The data was split 60/10/30 for training, validation, and testing, as is standard for many machine learning analyses, the. AUROC, AUPRC, NPV, PPV, sensitivity and specificity were reported on the testing set, in addition to confidence intervals generated by bootstrapping. Two of the inflammatory markers, LDH and C-reactive protein, exhibited the highest feature importance using a permutation test. Sensitivity analyses further demonstrated the utility of these inflammatory markers as additions to the baseline model. The authors make note of the limitations surrounding the generalizability to outpatient settings and the fairly high number of immunocompromised patients among the cases.</p>
<p>Key strengths:</p>
<p>1. This paper drew on previous literature to choose the most informative laboratory features to include in the model. All of the features in the model are commonly and easily obtained in the hospital setting, even in resource-poor areas.</p>
<p>2. The authors reported a variety of related performance metrics that all demonstrated the algorithm’s ability to capture true positives and limit false negatives. This model performed very well, notable demonstrated by the AUROC, sensitivity, and NPV. Prioritizing sensitivity and NPV are of keen clinical importance in this context and especially during a pandemic.</p>
<p>3. Finally, the authors used Python’s Scikit-learn package to perform the machine learning analyses, a highly accessible and open source software. They have agreed to make all of their code public and are in the process of creating a wed/mobile application for expanded use.</p>
<p>Suggestions for improvement:</p>
<p>1. Nearly 2000 patients who were tested for COVID-19 were excluded from this analysis due to incomplete laboratory measures. It would be helpful to provide some information or comments on why these patients did not have these particular lab measures, and if this may result in selection bias (for more severe cases). For example, were these excluded patients more likely to be negative or have mild cases of COVID-19? At a minimum, this limitation should be acknowledged.</p>
<p>2. Relatedly, under study design in the Methods section, the authors note that their features were selected in part based on higher values in those with severe COVID-19. This should also be noted in the limitations, given that generalizability to patients with milder cases of COVID-19 is unclear.</p>
<p>3. The authors provided no explanation for their choice of machine learning (ML) algorithms. Granted, the seven listed methods are all classification methods within Scikit-learn’s supervised machine learning models. It would nevertheless be useful to include a rationale or references for why these seven were specifically chosen.</p>
<p>4. Lastly, the authors stated that “We compared seven machine learning models…” (Methods, Machine learning analysis) but provided no data, figures, or discussion on this ‘comparison’. An explanation or figure summarizing individual model performance would provide additional clarity to this statement.</p>
<p>**********</p>
<p>
<!--  <font color="black">  -->
6. PLOS authors have the option to publish the peer review history of their article (
<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>
). If published, this will include your full peer review and any attached files.
</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>
<bold>Do you want your identity to be public for this peer review?</bold>
For information about this choice, including consent withdrawal, please see our
<ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>
.
<!--  </font>  -->
</p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0239474.r002" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0239474.r002</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Urbanowicz</surname>
<given-names>Ryan J.</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Ryan J. Urbanowicz</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>
This is an open access article distributed under the terms of the
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0239474" document-id-type="doi" document-type="article" id="rel-obj002" link-type="peer-reviewed-article"/>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">14 Sep 2020</named-content>
</p>
<p>PONE-D-20-20126 </p>
<p>A machine learning algorithm to increase COVID-19 inpatient diagnostic capacity </p>
<p>Dear Dr. Goodman-Meza:</p>
<p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
<p>
If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact
<email xlink:type="simple">onepress@plos.org</email>
.
</p>
<p>
If we can help with anything else, please email us at
<email xlink:type="simple">plosone@plos.org</email>
.
</p>
<p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
<p>Kind regards, </p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. Ryan J. Urbanowicz </p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
</body>
</sub-article>
</article>